What this guide is and is not
People searching for a semaglutide dosage chart usually want two things: to understand the shape of treatment, and to check what they have been told against something official. This guide gives the first and helps with the second. It reports the dosing schedule exactly as the FDA-approved prescribing information for Wegovy® states it, explains why the label is built that way, and then describes how a compounded prescription differs in the way a dose is set and measured.
What it is not is a set of instructions. Nothing here is advice on what dose to take or when to change it. The schedule below describes the approved product. With a compounded prescription, which is what Bodi Envi’s programs may include, your licensed provider sets your dose and any change to it, and the pharmacy’s measuring instructions govern how it is drawn up. Personalized Compounded semaglutide is not FDA-approved and was not studied in the trials the label reports. Your provider is the person to ask.
The schedule as the Wegovy® label states it
The Wegovy® prescribing information sets a recommended starting dose of 0.25 mg injected under the skin once weekly and a table of increases every four weeks, which it presents as the recommended starting dosage and dosage escalation for all approved indications in adults and adolescents aged twelve and older.
| Weeks | Once weekly dose per the Wegovy® label | Stage |
|---|---|---|
| 1 to 4 | 0.25 mg | Starting dose |
| 5 to 8 | 0.5 mg | Escalation |
| 9 to 12 | 1 mg | Escalation |
| 13 to 16 | 1.7 mg | Escalation |
| 17 onward | Maintenance dose per the indication | Maintenance |
For weight reduction in adults, the label lists the maintenance dose as either 1.7 mg or 2.4 mg once weekly, with 2.4 mg recommended, and says to consider treatment response and tolerability when selecting it. It adds that for adults who tolerate 2.4 mg for at least four weeks and for whom additional weight reduction is clinically indicated, the dose may be increased to a maximum of 7.2 mg once weekly. For the label’s other indications the maintenance doses differ, and the label sets them out separately.
Every line of that table is a statement about Wegovy®, the branded pen. It is reported here because it is the only FDA-approved description of how semaglutide for weight management is meant to be escalated, and because a compounded prescription is written by a provider who knows it.
Personalized compounded medications differ from commercially available brand-name products in formulation, concentration, excipients, preparation methods, and other characteristics. Accordingly, clinical data from studies involving brand-name products should not be assumed to apply to personalized compounded formulations.
At this time, the studies referenced above have not evaluated the specific personalized compounded formulations being provided. Therefore, no claims of equivalence in safety, efficacy, quality, or clinical outcomes should be inferred from these studies.
Why the steps exist
The label gives one reason for the whole structure: follow the dosage escalation to reduce the risk of gastrointestinal adverse reactions. Nausea, diarrhea, vomiting and constipation are the most common side effects the label reports, at 44, 30, 24 and 24 percent respectively among adults on 2.4 mg in the weight reduction trials against 16, 16, 6 and 11 percent on placebo, and the body needs time to adjust to each level before the next. STEP 1, the reference trial published in the New England Journal of Medicine in 2021, escalated over sixteen weeks before its 52 weeks at the maintenance dose, and its authors describe the nausea and diarrhea seen as typically transient and mild to moderate, subsiding with time.
The label builds in flexibility for exactly that reason. It says that if a patient does not tolerate a dose during escalation, a provider may consider delaying the next step by four weeks. It says to consider treatment response and tolerability in choosing between the maintenance doses. And in its missed dose section, it says that if two or more consecutive doses are missed, escalation should be restarted at a lower dose to reduce the risk of gastrointestinal reactions.
The label’s pharmacokinetics explain the timing. Semaglutide has a half-life of approximately one week, which is why the medication is weekly and why each step is held for four weeks before the next: it takes several weeks on a dose for the level in the body to settle. The label also notes that semaglutide remains in the circulation for about five to seven weeks after the last dose.
Personalized compounded medications differ from commercially available brand-name products in formulation, concentration, excipients, preparation methods, and other characteristics. Accordingly, clinical data from studies involving brand-name products should not be assumed to apply to personalized compounded formulations.
At this time, the studies referenced above have not evaluated the specific personalized compounded formulations being provided. Therefore, no claims of equivalence in safety, efficacy, quality, or clinical outcomes should be inferred from these studies.
Missed doses, as the label describes them
The label’s missed dose guidance for the injection is short. If one dose is missed and the next scheduled dose is more than two days away, the missed dose should be taken as soon as possible. If the next scheduled dose is less than two days away, the missed dose is skipped and dosing resumes on the regular day. If two or more consecutive doses are missed, escalation restarts at a lower dose.
Those rules describe the branded product. If you miss a dose of a compounded prescription, message your care team through the patient portal and follow their answer rather than applying the label yourself, because your provider may have set a different plan and because a compounded vial is measured differently, as the next section explains.
Personalized compounded medications differ from commercially available brand-name products in formulation, concentration, excipients, preparation methods, and other characteristics. Accordingly, clinical data from studies involving brand-name products should not be assumed to apply to personalized compounded formulations.
At this time, the studies referenced above have not evaluated the specific personalized compounded formulations being provided. Therefore, no claims of equivalence in safety, efficacy, quality, or clinical outcomes should be inferred from these studies.
How a compounded vial is measured differently
The branded product comes as a single-dose pen or syringe at each strength, and a multi-dose pen that delivers four weekly doses of 2.4 mg. The dose is set by the device. The label lists the strengths as 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg and 7.2 mg per pen.
Personalized Compounded semaglutide typically comes as a vial of solution, though the exact presentation depends on the pharmacy, and the dose is drawn up with a syringe. That changes the arithmetic. A vial has a concentration, so many milligrams of semaglutide per milliliters of solution, and a dose in milligrams corresponds to a volume in milliliters or in the unit markings on an insulin syringe. The same milligram dose is a different volume in a vial of a different concentration, and a vial from one pharmacy may not match a vial from another. The number your provider gives you and the number on your syringe are two different things connected by the concentration printed on your pharmacy label, and that label is the only place to get the conversion for your vial.
This is the origin of the FDA’s most specific concern about compounded GLP-1 drugs. Its statement dated September 1, 2026 reports multiple adverse events, some requiring hospitalization, that may be related to dosing errors with compounded injectable semaglutide, resulting from patients measuring and self-administering incorrect doses and from providers miscalculating doses. The agency encourages patients to talk with their provider or compounder about how to measure and administer the intended dose. The statement also reports adverse events in patients prescribed personalized compounded semaglutide in doses beyond what the approved label describes, whether by a larger single dose, more frequent dosing or a faster escalation, with symptoms including nausea, vomiting, diarrhea, abdominal pain and constipation, and it asks providers to be vigilant about doses and titration schedules.
The practical rules are the ones every guide on this site repeats. Use the pharmacy’s measuring instructions. Use a new sterile needle and syringe each time. Ask your care team before injecting if anything is unclear. Never change your own dose. And be aware that the FDA recommends discarding a multi-dose vial of a sterile medication 28 days after first use, even if medication remains and even if the compounder’s instructions say otherwise.
What a provider does with the label
A compounded prescription is written by a licensed provider who knows the label schedule and applies clinical judgment to your case. The provider sets your starting dose, decides when and whether to increase it, and can hold a dose or lower it if you are not tolerating it, which are the same kinds of decision the label describes for the branded product. Bodi Envi’s programs are structured so that this stays a clinical decision: for applicable programs, pricing does not increase based solely on dosage strength, so moving up or staying put has no effect on what you pay.
That also means the schedule above is a reference for your conversation, not a target. If your provider’s plan differs from the label, the plan is what to follow, and the right response to a question about it is to ask through the patient portal.
When to contact your provider
The label’s patient counselling section asks providers to tell patients to contact them for severe or persistent gastrointestinal symptoms, and to report promptly any persistent nausea, vomiting or diarrhea because of the risk of dehydration and kidney injury. The symptom guides on this site to nausea and to the first week of treatment cover this in more detail. For a compounded prescription, the specific triggers to message your care team are: you are unsure how to measure a dose, you have missed a dose or more than one, you are not tolerating a step, or you have changed or started another medication. Seek emergency care for anything severe.
How Bodi Envi’s program approaches dosing
Bodi Envi is a LegitScript-certified U.S. telehealth platform that connects eligible adults with licensed healthcare providers for personalized medical weight-management care. It is not a medical practice, pharmacy or medication manufacturer. Clinical services for applicable programs are provided by Wasef Health, PC, and a licensed provider decides whether treatment is appropriate and sets the plan. Prescriptions are dispensed by third party U.S. 503A licensed compounding pharmacies, whose label carries the concentration and measuring instructions for your vial.
The published price for the personalized compounded semaglutide program runs from $155 per month billed monthly to $125 per month on a twelve month plan, and it is the same at every dose. Personalized Compounded semaglutide is not FDA-approved and is not equivalent to Wegovy®. This guide is general information and not medical advice; the schedule it reports describes the branded product; and your licensed provider is the person to ask about your own dose.